Stock KROS KEROS THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Keros Therapeutics, Inc.

Equities

KROS

US4923271013

Real-time Estimate Cboe BZX
Other stock markets
 10:06:53 2024-06-04 am EDT 		5-day change 1st Jan Change
50.2 USD +3.14% Intraday chart for Keros Therapeutics, Inc. +2.87% +26.13%
May. 28 Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors and to Serve as A Member of the Nominating Committee, Effective June 1, 2024 CI
May. 08 Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000 MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Keros Therapeutics to Host a Corporate Update Conference Call and Webcast
AQ
Keros Therapeutics to Present at Goldman Sachs 45th Annual Global Healthcare Conference
AQ
Keros Therapeutics Appoints Jean-Jacques Bienaimé to its Board of Directors
AQ
Keros Therapeutics, Inc. Appoints Jean-Jacques Bienaimé to Its Board of Directors and to Serve as A Member of the Nominating Committee, Effective June 1, 2024
CI
Keros Therapeutics to Present at the 29th Annual Congress of the European Hematology Association
AQ
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q1 Revenue $83,000
MT
Keros Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Keros Therapeutics Reports Recent Business Highlights and First Quarter 2024 Financial Results
AQ
Morphic Holding Names Simon Cooper as Chief Medical Officer
MT
Keros Therapeutics Shares Rise After FDA Fast Track Designation for Potential Anemia Drug
MT
Keros Therapeutics Gets FDA Fast Track Designation for Anemia Drug
MT
Keros Gets FDA Fast-Track Designation for Lead Drug KER-050
DJ
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
AQ
Keros Therapeutics Announces U.S. FDA Fast Track Designation for KER-050 in Lower-Risk Myelodysplastic Syndromes
CI
Keros Therapeutics to Present at Leerink Partners 2024 Global Biopharma Conference
AQ
Keros Therapeutics, Inc. Announces Resignation of Simon Cooper, M.B.B.S., as Chief Medical Officer, Effective March 12, 2024
CI
Keros Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Keros Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023
CI
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results
AQ
Earnings Flash (KROS) KEROS THERAPEUTICS Reports Q4 Revenue $143,000
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. KROS Stock
  4. News Keros Therapeutics, Inc.